Bupropion SR was introduced for smoking cessation in the US in 1997. This review
assesses the efficacy and safety of bupropion SR for treatment of tobacco dependence …

Tobacco use, particularly cigarette smoking, is now a global pandemic. The expected
morbidity and mortality from smoking-attributable diseases will continue to rise for the next …

The advent of bupropion hydrochloride sustained release (Zyban) has heralded a major
change in the options available for smoking cessation pharmacotherapy. Bupropion is a …

Sustained-release bupropion (bupropion SR) was first launched in the US in 1997 as an aid
to smoking cessation and has since been launched in many other countries. Adverse events …

Sustained release bupropion (amfebutamone) is a non-nicotine agent that is indicated as an
aid to smoking cessation. In 2 large well designed clinical trials, sustained release …

Tobacco use is a global pandemic. The most common pharmacological treatments of
tobacco use and dependence include nicotine replacement therapy and nonnicotine …

Background Many persons who attempt to quit smoking have made previous unsuccessful
attempts to quit with pharmacologic aids. An understanding of the impact of these previous …

Nicotine addiction is a chronic relapsing condition that can be difficult to treat. Until recently,
pharmacological options for the treatment of tobacco dependence were primarily limited to …

Cigarette smoking remains the largest preventable cause of premature death in developed
countries. Until recently nicotine replacement therapy (NRT) has been the only recognised …

Background: Knowledge pertaining to the effectiveness of smoking cessation treatments and
patient characteristics that may affect success may enable smokers and clinicians to select …